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ABSTRACT(
Hepatitis C virus (HCV) is a blood borne virus affecting the liver. Globally, it is estimated 
that approximately 6 million children live with HCV infection today. The main transmission 
route in children today is vertical transmission. Before the introduction of blood donor 
screening in 1992, blood transfusion was an important source of infection. The aim of this 
thesis was to study epidemiological and immunological aspects of exposure to HCV early in 
life, with specific emphasis on transmission routes. 
In study I we investigated blood transfusions in the neonatal period as transmission route in 
chronic HCV infection. We included 230 patients born 1960-75 with chronic HCV infection. 
Of those, 98 had unknown and 128 had known transmission route. Four out of 230 (1.7 %) 
had received blood transfusion in the neonatal period. None were aware of their transfusion 
history at the time of diagnosis. Three patients underwent successful antiviral treatment. 
In study II the prevalence of HCV infection and HCV testing as well as infection outcome 
was studied in a cohort of 676 childhood cancer survivors in Stockholm. The prevalence of 
HCV testing was 34 % (233/676) for the whole cohort. Eleven out of 233 (5 %), were HCV-
RNA positive, which is 10 times higher than the Swedish population prevalence. A 
comparison of the effectiveness of screening methods showed that active tracing screening 
was far more effective in terms of test uptake (p < 0.001). The majority of the infected 
patients underwent successful antiviral treatment. 
In study III we investigated the impact of IL28B genotype on vertical HCV transmission. 
IL28B genotype is known to be important for spontaneous clearance and interferon treatment 
response. We included 59 mothers with chronic HCV infection and 123 children (47 infected 
and 76 uninfected) born of HCV infected mothers. Neither the mothers’, nor the children’s 
IL28B genotype was associated with the risk of vertically transmitted HCV (HCV-VT).  
In study IV HCV specific T cell responses were studied in children born of mothers with 
chronic HCV infection. HCV specific T cell responses were investigated by IFNγ production 
and proliferation upon stimulation with viral antigens in vitro. We found an HCV specific T 
cell response in 73 % (11/15) of the mothers, 67% (6/9) of infected children and 56 % of 
uninfected/exposed (18/32) children. The two exposed pediatric groups had a significantly 
higher proportion of T cell responders compared to controls (p< 0.02). We detected HCV 
specific T cell responses already in exposed newborns, suggesting a prenatal exposure to viral 
antigens. 
In conclusion, low awareness and prevalence of HCV testing in pediatric transfusion risk 
groups in combination with high HCV prevalence justifies active tracing screening of risk 
groups. IL28B genotype is not associated with HCV-VT, suggesting that other 
immunological factors need to be investigated. A high proportion of exposed but uninfected 
children have HCV specific T cell responses, suggesting that prenatal exposure to viral 
antigens might be more common than previously thought.,
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1( INTRODUCTION(
Hepatitis C virus (HCV) infection is a blood borne disease affecting the liver. Chronic HCV 
infection is an important global health issue, affecting an estimated 71 million people 
worldwide (1). Among them, around 6 million are children (2). The majority of HCV 
infected individuals are unaware of their infection status (1, 3). Chronic HCV infection is 
usually asymptomatic the first 20 years, but might eventually progress into liver cirrhosis and 
hepatocellular carcinoma (HCC) (3). The introduction of highly effective and safe direct 
acting antiviral (DAA) treatment has revolutionised the treatment outcome of HCV infection, 
which is now considered a relatively easy-to-treat disease. The World Health Organisation 
(WHO) has set a goal of eliminating viral hepatitis as a public health threat by the year of 
2030 (1). To reach this goal, up scaling of screening methods to find yet undiagnosed patients 
and prevention strategies to reduce viral transmission are needed.  
 
This thesis aims to explore the past and present main transmission routes of HCV in children, 
namely vertical transmission from mother to child during pregnancy or delivery and previous 
blood transfusions. We study the association between immunological factors and the risk of 
vertical transmission and the HCV prevalence and screening outcomes of paediatric 
transfusion risk groups.  
(
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2( BACKGROUND(
2.1( HISTORY(
In the 1970s a previously not described post transfusion viral hepatitis infection was 
suggested and named non-A, non-B (NANB) hepatitis, since it lacked serological markers of 
both hepatitis A and B (4). However, it took until 1989 before the new virus, named hepatitis 
C, was isolated and characterized. Isolation was performed by a novel, blind 
immunoscreening method in which antibodies derived from a clinically diagnosed NANB 
hepatitis patient were used to identify a cDNA clone encoding an epitope within the hepatitis 
C virus. (5). Serological tests were developed and became available in Sweden by 1990. 
Blood donor screening for hepatitis C by second generation antibody testing was introduced 
in Sweden by January 1st 1992. Interferon treatment was available already in the 1980’s, later 
with the addition of ribavirin (6). This interferon-based injection therapy was only moderately 
effective and had serious side effects. Intensive virological research led to the development of 
the highly effective oral direct-acting antiviral (DAA) treatment introduced in 2011 (7-9). 
!
2.2( EPIDEMIOLOGY(
The World Health Organization (WHO) has recently, in the “World hepatitis report 2017”, 
recalculated the global burden of chronic hepatitis C infection. The number of individuals 
assumed to be infected was thus reduced from previously 170 million people to 71 million 
people; the new number is based on updated estimations (1, 2). The most important reason 
for this big difference in prevalence is that the new estimation is based on viremic infections 
(i.e. positive HCV RNA) instead of serologic (HCV-antibody) status which was used 
previously (1) . The new estimate of 71 million people constitutes a global HCV prevalence 
of 1 %. It is estimated that approximately 6 million children under the age of 15 years have 
viremic HCV infection, which gives a prevalence of around 0.3% (2). Worldwide, in 2015 a 
total of 1.75 million new cases of chronic hepatitis C were diagnosed and the most common 
routes of HCV transmission were injection drug use (IDU) and unsafe health care procedures. 
It is estimated that 2.3 million people with HCV also are co-infected with human 
immunodeficiency virus (HIV). 
The global incidence rate of HCV infection has decreased during many years, but in the US a 
170 % increase in incidence rate of acute HCV infection among young people in nonurban 
counties was seen from 2006-2012, with the steepest increment in 2011-2012 (10). The 
explanation for this alarming trend is the increasing drug use among young people in the US. 
The actual incidence of acute HCV infection (see below for details) is hard to calculate since 
the infection is mainly asymptomatic. Chronic HCV infection is unevenly distributed around 
the world with highest prevalence in Eastern Europe, Central Asia and Egypt (Fig. 1). The 
morbidity and mortality rates caused by chronic HCV infection have increased since year 
2000 and it is estimated that around 400 000 people die from HCV related causes every year.  
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Unlike Malaria, Tuberculosis and HIV, the mortality trend for viral hepatitis is increasing 
(11).  
In Sweden, the prevalence of anti-HCV among adults is calculated to be around 0.5 % (12). 
The majority of these patients was born in 1950-1960 and they were infected mainly by IDU 
during the 1970s to 1980s. In Sweden, notification of HCV infection is mandatory to report 
to the Public Health Agency of Sweden by clinicians and laboratories according to the 
Communicable Diseases Act. Around 2000 new cases of chronic HCV infection are reported 
every year (13). 
(
Figure 1. Global prevalence of hepatitis C virus infection in 2017. 
Reprinted by permission from Springer Nature: Nature Reviews Disease Primers, Hepatitis C virus 
infection, Michael P. Manns et.al, © 2017. 
(
2.3( TRANSMISSION(ROUTES(AND(HCV(SCREENING(
Hepatitis C virus infection is a blood-borne disease and globally the most common routes of 
infection are injection drug use (IDU), blood product transfusions, contaminated health care 
equipment, sexual transmission and mother-to-child transmission during pregnancy or 
delivery (14).  
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2.3.1( Blood(transfusions(and(lookQback(screening(
In countries where general blood donor screening for HCV was introduced in the early 
1990’es, infection through contaminated blood products has almost completely vanished as 
transmission route. However, in some low-income countries, transfusion of blood products 
and contaminated health care equipment is still a common source of infection (1). Many 
people living with chronic hepatitis C today were infected by contaminated blood through 
transfusions before 1992. Nationwide screening campaigns and so called look-back studies of 
blood product recipients have been carried out in some countries in order to detect and treat 
HCV carriers (15, 16). There are two types of look-back studies; general look-back studies 
that aim at a specific risk group, and targeted look-back studies that proceed from a known 
donor of HCV contaminated blood. Unawareness of previous blood transfusion during 
childhood is common. Children, with a long life expectancy, run a higher lifetime risk of 
HCV related complications than adults.  
The Swedish National Board of Health and Welfare launched a national hepatitis C screening 
campaign in 2007 (17). Individuals who recalled a blood product transfusion in the years 
1965-1991, were by advertisements in media recommended to take a test for anti-HCV. 
Three specific paediatric risk groups with a high estimated prevalence of blood transfusions 
were identified: 
1., Patients treated for prematurity, in particular those who had undergone neonatal 
exchange transfusion. 
2., Patients treated for childhood cancer. 
3., Patients who had undergone open heart surgery during childhood. 
By the end of year 2010, 65 000 subjects in the Sweden had been tested for HCV within the 
screening campaign, of whom 0.9 % were anti-HCV positive and 0.6 % HCV-RNA positive 
(17). The majority was born in the 1930-50’s, i.e. presumably not belonging to any of the 
three specific pediatric risk groups. A large group of women was found to be infected by 
blood transfusion during childbirth. For comparison, a summary of the screening campaign in 
the region of Västra Götaland demonstrated a prevalence of HCV viremia of 0.8 % (15).  
General look-back studies on recipients of neonatal blood transfusions have shown a 
prevalence of HCV viremia of around 1-3 % (18, 19). However, an Italian study of recipients 
of neonatal micro transfusions during 1968-74 reported a very high prevalence of 30 % HCV 
viremia (20). The same group did later a targeted look-back study on 31 recipients of mini 
transfusions given at birth in 1968 from a common infected donor and found 58 % to be anti-
HCV positive and 52 % also HCV-RNA positive, none of them were aware of their 
transfusion history (21). Similar results were found in a Swedish targeted look-back study 
from 1996 on transfusion recipients of infected donors , with 93 % anti-HCV positive and 59 
% HCV-RNA positive (22). Studies have confirmed that at least half of neonatal transfusion 
recipients are unaware of their previous transfusion history (19, 23). Vogt et al. studied 
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patients who underwent cardiac surgery during childhood before 1991and found a prevalence 
of 8 % positive HCV-RNA (24).  
Previous international studies of childhood cancer survivors have reported an HCV-RNA 
prevalence of around 6-40 % in this risk group, depending on which malignancies that were 
included (25-27). An increased risk of HCV related complications and a more advanced liver 
disease due to the additional effect of cytotoxic and immunosuppressive treatment have been 
shown in some studies, while others claim no additional effect (27-29).  
 
2.3.2( Vertical(transmission((MotherQtoQchild(transmission)(
Vertical transmission of HCV (HCV-VT), also called mother-to-child transmission (MTCT), 
during pregnancy or delivery is nowadays the most common route of HCV transmission in 
children. The risk of HCV-VT in children of HIV negative mothers is estimated to be around 
5 % (range 1-10 %), (Table 1) (30, 31). HIV co-infection doubles the risk of HCV-VT (Table 
1).  Two early Swedish studies on HCV-VT showed a low rate of transmission (32, 33).  
 
 
Table 1. Pooled estimates of risk of hepatitis C virus (HCV) vertical transmission among children 
≥18 months born to HCV antibody–positive and RNA-positive mothers, by maternal HIV serostatus. 
With permission from Oxford University Press. Benova et al. Vertical Transmission of Hepatitis C 
Virus: Systematic Review and Meta-analysis. Clin Infect Dis. 2014;59(6):765-773. 
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The exact time point of transmission is difficult to determine, but around 1/3 of all cases are 
thought to occur during pregnancy and the rest during delivery (34). Potential risk factors for 
HCV-VT have been investigated in numerous studies. Clinical factors associated with an 
increased risk of HCV-VT are co-infection with HIV, high maternal viral load, prolonged 
rupture of membranes and possibly fetal scalp monitoring during labor (35-39). One 
multicenter study described a two times higher risk of vertical HCV infection in girls 
compared to boys, the reason for this finding is unclear (40). Delivery mode or breast feeding 
have not been shown to influence the risk, and mothers with HCV infection are not 
discouraged from vaginal delivery or breastfeeding (38). All children of HCV infected 
mothers are recommended to be tested for anti-HCV at the age of 18 months when passively 
transferred maternal antibodies have disappeared. No country has implemented general 
antenatal HCV screening of pregnant women. Only pregnant women considered to be at risk 
(e.g. previous or present drug use, blood transfusion before 1992) are currently tested. The 
reason for not including HCV in antenatal screening programs is lack of interventions to 
prevent HCV-VT. However, the group of  HCV infected women that lack known risk factors 
is missed if only patients from risk groups are included in antenatal screening (41).  
Despite viral exposure of the fetus during delivery, the rate of HCV-VT is low compared to 
the vertical transmission rate of other viral infections, such as HIV and hepatitis B virus 
(HBV) (42). The reason for the comparatively low risk of HCV vertical transmission remains 
unclear, but various immunological factors have been suggested to play a role, for example 
human leukocyte antigen (HLA) genotype, HCV-specific T cell responses and HCV 
neutralizing antibodies (43-46). Difference in maternal HCV genotype does not seem to 
influence the risk of HCV-VT (38). 
 
2.3.3( Injecting(drug(use(
The most common source of HCV infection in adults is injecting drug use (IDU) and sharing 
of needles. The term PWID (people who inject drugs) is preferred when referring to the 
subjects as a group. It is estimated that 8 % (5.6 million people) out of the 71 million HCV 
infected people are active drug users (1). PWID accounts for 23 % of new HCV cases 
worldwide (1). In Sweden, around 39 % of persons notified with HCV infection report IDU 
as transmission route (13). A recent study of PWID in Stockholm showed an 82% prevalence 
of anti-HCV and 76% prevalence of HCV-RNA (47). In Stockholm the first needle exchange 
program was introduced as late as in 2013. Needle exchange programs for PWID need to be 
combined with HCV treatment and opioid substitution treatment to reduce the HCV 
transmission rate in this group (48, 49). Efforts to screen and treat this risk group have been 
of various success, mainly due to lack of reachability. The risk of reinfection is higher in 
PWID, but nevertheless ability to reach this group that otherwise has little interaction with 
health care services, remains a key factor to control the HCV epidemic (47). Screening and 
treating HCV infected prisoners, a group with high proportion of PWID have been effective 
in many countries (50).  
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2.3.4( Other(transmission(routes(
 
A large proportion of HCV infections are notified as unknown transmission route. In Sweden, 
approximately 45 % report unknown transmission route when diagnosed with HCV infection 
(13). Studies have shown that careful risk factor screening can reduce this proportion. A 
remote history of IDU was the true source of infection in almost all cases with reported 
unknown transmission route in a study by Flamm et al. (51). The contribution of other 
possible transmission routes to the burden of HCV infection is small but not negligible. 
Transmission of HCV has been described in tattooing (52), intranasal drug use (53), sexual 
contacts (with a higher risk for men who have sex with men (54)) and (in low-income 
countries) the use of unsterilized health care equipment (1). Unawareness of previous blood 
transfusions, especially if given in the neonatal period, might also explain some of the cases 
with unknown transmission route (20, 21). 
 
2.4( (HEPATITIS(C(VIROLOGY(
HCV is a single stranded enveloped RNA virus belonging to the Flaviviridae family. Its 
genome consists of 9600 nucleotides encoding a large polyprotein of about 3000 amino acids. 
The polyprotein is cleaved by host and viral proteases into 10 known proteins; three structural 
(core and envelope 1 and 2) and seven non-structural proteins (P7, NS2, NS3, NS4A, NS4B, 
NS5A and NS5B) (Fig. 2). The HCV polymerase is prone to error reading, which gives rise 
to a high mutation rate and genetic variability of the virus. This is one of many viral 
mechanisms for evasion of the host immune system. Currently there are 7 known HCV 
genotypes with different geographic distribution. Until now different treatment modalities 
were needed for specific genotypes.   
Figure 2.  The HCV polyprotein and its functional protein products  
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2.5( HEPATITIS(C(IMMUNOLOGY(AND(VIRAL(EVASION(
The virus infects predominantly hepatocytes in the liver. Within a week after infection 
viremia can be detected as positive HCV RNA in peripheral blood. The innate immune 
system recognizes HCV and induces an early interferon (IFN) response (55). However, the 
virus manages to attenuate the Janus kinas-signal transducer and activator of transcription 
(JAK-STAT) pathway which results in impaired host IFN production (56, 57). As a 
consequence of failure of the innate immune system to control viral replication, the HCV 
RNA levels increase dramatically the first weeks after infection. The adaptive immune 
response, including neutralizing antibodies and HCV specific T cells, is activated about 4-8 
weeks after infection (58). Patients with acute HCV show broad HCV-specific T cell 
responses against different viral epitopes (58). This broad immune response is lost over time 
in the case of chronic infection, and viral escape mutations emerge, that contribute to viral 
evasion of the host immune system (59). The effector cells in chronic HCV infection are 
mainly CD8+ T cells, which are dependent on help from CD4+ cells. In chronic HCV 
infection the CD4+ cells are deficient which contributes to exhaustion and dysfunction of 
CD8+ effector cells that are unable to eradicate the virus and chronicity is established (55). 
Spontaneous resolution occurs in about 20 % of acutely infected patients and is dependent on 
an intense and broad IFN-γ response, mediated by HCV specific T cells. The humoral 
response in HCV infection is unable to clear the infection; however neutralizing antibodies 
might yield some degree of protection (60, 61).  
Protective immunity with decreased duration of infection upon reinfection has been shown in 
humans, although sterilizing immunity has not been proven (62). Studies on HCV specific T 
cell responses in individuals at high risk of HCV infection have shown that individuals with 
strong and broad responses might be partially protected from chronic infection, and that 
reinfection in T cell responders yielded a shortened viremia period (63-67). Chimpanzee 
rechallenge studies have demonstrated that HCV specific T cell responses were associated 
with spontaneous clearance and protection from chronic reinfection (68, 69). It has been 
hypothesized that children who are exposed to HCV antigens in utero might be endowed with 
some sort of protective immunity (44). Previous in vitro studies have shown that vertical 
exposure to HCV induces virus-specific cell-mediated immune (CMI) responses in 
uninfected children of mothers with HCV infection (44, 70). 
Due to insufficiency of the innate and adaptive immune system in combination with viral 
immune evasion strategies the infection becomes chronic with risk of developing liver 
fibrosis in about 75-80 % of infected patients (Fig. 3) (71, 72). 
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Figure 3. Kinetics of subsequent processes: first viral replication (HCV RNA), second innate 
immunity, third HCV-specific CD4+ and CD8+ T cell responses, fourth liver inflammation (ALT) and 
fifth liver damage (fibrosis). Reprinted from Curr Opin Virol 2013;3(4):461-7, Claassen et al, Role of 
T cell immunity in hepatitis C virus infections, with permission from Elsevier  
,
2.6( (IL28B(SINGLE(GENETIC(POLYMORPHISM(
In 2009, Ge et al. described that single genetic polymorphism (SNP), near the gene for 
Interleukin 28B (IL28B) on chromosome 19 (SNP rs12979860) is associated with better 
treatment response in interferon-based treatment (73). The IL28B gene encodes type III 
interferon, IFN-λ3 (IFNL3). IL28B has recently been renamed IFNL3. It was also shown that 
spontaneous viral clearance was strongly associated with the favourable IL28B genotype C/C 
(74). The favourable effect of the C allele is particularly strong in patients infected with HCV 
genotype 1, and slightly less pronounced regarding viral genotype 2 and 3 (75, 76). Results 
from paediatric studies on spontaneous clearance and IL28B genotype are in line with the 
adult observations (77-79). 
The product of the IL28B gene, the IFNL3, mediates its effect on treatment results and 
spontaneous clearance by activating the JAK-STAT pathway. The activation induces 
interferon-stimulating genes (ISGs) that have antiviral activity. Presence of the unfavourable 
T allele results in less IFNλ3 expression (78). IL28B/IFNL3 genotype has, in the era of DAA 
treatment, no longer any clinical implications on treatment decisions. However, it is still 
relevant for the rate of spontaneous clearance. 
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2.7( (DIAGNOSIS(OF(HEPATITIS(C(VIRUS(INFECTION((
The HCV antibody test is used to screen for hepatitis C infection and the HCV RNA test to 
confirm or exclude ongoing infection. HCV antibodies are analysed by enzyme immune 
assay (EIA), where recombinant antigens are used to capture circulating antibodies (80). To 
confirm a positive EIA test, a recombinant immunoblot assay (RIBA) is used (81). Reverse 
transcriptase polymerase chain reaction (PCR) and real time PCR is used to detect and 
quantify HCV RNA (82).  
HCV RNA can be detected in blood within a week after infection, while HCV antibodies are 
developed 6-8 weeks later (83). HCV antibodies remain positive for many years in patients 
who have cleared the infection spontaneously or after treatment (84). The diagnosis of acute 
hepatitis C infection is made by detection of HCV RNA in blood, and if still detectable six 
months later the infection has developed into chronic hepatitis C.  
The definition of spontaneous clearance is two negative HCV RNA tests taken at least 12 
weeks apart. One negative HCV RNA test is not sufficient to declare spontaneous clearance 
since transient suppression of viremia has been demonstrated (85). Approximately 25 % of 
adults spontaneously clear the acute infection, while 75 % develop a chronic infection (86). 
The majority of patients who spontaneously clear the infection do that within a period of six 
months from infection; only 11 % clear the infection later (86). Factors associated with 
spontaneous HCV clearance are female gender, low viral load and young age at infection, 
viral genotype 1 and IL28B genotype C/C (86, 87). 
To determine the amount of HCV related liver fibrosis and inflammation, a percutaneous 
liver biopsy can be performed. Histologically, the stage of liver fibrosis as well as the grade 
of inflammation is measured using different scoring systems. In Sweden the Ludwig and 
Batts score is the most commonly used, which grades liver inflammation 0-4 and stages liver 
fibrosis 0-4 and (88). Liver biopsy is not a risk free event and serious complications such as 
massive bleeding do occur occasionally (89). In recent years, transient liver elastography, 
which is a non-invasive ultrasound based method to measure liver stiffness or elasticity, has 
been developed and is now commonly used to evaluate the degree of liver fibrosis (90).  
 
2.8( (NATURAL(HISTORY(OF(HCV(INFECTION(IN(ADULTS(
The acute infection is short-term and usually asymptomatic but around 10 % develop 
hepatitis symptoms such as jaundice, fatigue and nausea (91). Liver transaminases are usually 
elevated.  
The chronic infection is usually life-long and asymptomatic. However, it leads to progressive 
liver inflammation and silent development of liver fibrosis resulting in end-stage liver disease 
20-30 years later in 20-50 % (71, 72). Around 50 % of those infected are unaware of their 
HCV status and it is estimated that only 20 % of those infected have been diagnosed (1, 92). 
The first symptoms might in some cases, be related to already established liver cirrhosis such 
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as jaundice, ascites and gastrointestinal bleeding. The risk of developing hepatocellular 
carcinoma (HCC) is clearly elevated in patients with HCV related liver cirrhosis, with an 
annual HCC rate of around 1-4 % in Europe and USA (93, 94). A Swedish study concluded a 
7 % absolute risk of developing primary liver cancer within 40 years of HCV duration (95).  
Patients with HCV related cirrhosis should thus participate in HCC surveillance programs 
including regular ultrasound scanning. The rate of HCV related liver fibrosis varies between 
individuals. Factors associated with a higher rate of fibrosis development are high age at 
infection, duration of infection, male gender, alcohol consumption, obesity, co-infection with 
HIV and viral genotype 3 (71, 96-98).  There are contradicting findings regarding the impact 
of IL28B genotype on development of liver fibrosis (99, 100). Hepatitis C infection can also 
give rise to extrahepatic manifestations such as cryoglobulinemia, membranous 
glomerulonephritis and lymphoproliferative disease (101). 
 
2.9( (NATURAL(HISTORY(OF(HCV(INFECTION(IN(CHILDREN(
In children HCV infection is considered to be less progressive, maybe due to lack of certain 
adult risk factors such as alcohol consumption. Most children have no clinical symptoms at 
all during childhood even though moderately elevated liver transaminases are common. 
However, some children and adolescents do develop an advanced liver disease with 
progressive fibrosis and even HCV related cirrhosis (102-104).  
The most common route of HCV infection in children nowadays is mother-to-child 
transmission during pregnancy or delivery (105, 106). The rate of spontaneous clearance after 
perinatal transmission is calculated to be around 20 % and the median time of clearance is 15 
months after infection (103). Factors associated with spontaneous viral clearance in vertically 
infected children are hepatitis C specific IFNγ immune response, IL28B genotype C/C and 
viral genotype 3 (70, 102, 107). There are conflicting data concerning the impact of abnormal 
ALT levels on the rate of spontaneous clearance in children (108-110). The high viral 
mutation rate gives rise to wide HCV genome diversity within each infected individual, 
termed HCV quasispecies. Those quasispecies helps the virus evade the host immune system, 
leading to higher risk of chronicity. The diversity is largest within the E2 region, which is 
also under selective pressure from HCV neutralizing antibodies (111). It has been shown that 
HCV-VT infected children have less diverse viral E2 region compared to their mothers which 
theoretically might contribute to higher rates of spontaneous clearance in young children, also 
suggesting that transient viremia might be more common than previously thought during the 
first 18 months of life (112).  
Extrahepatic manifestations of chronic HCV infection are rare in children, but a higher 
percentage of autoantibodies have been described. Presence of liver kidney microsomal 
antibody type 1 (LKM-1) was found in 10 % of children with chronic HCV infection and was 
associated with a higher degree of liver fibrosis (113, 114). Children with chronic hepatitis C 
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are recommended to be followed by yearly clinical check-ups including blood tests and 
assessment of liver fibrosis.  
 
2.10( HEPATITIS(C(TREATMENT(
Pegylated interferon in combination with ribavirin was the standard of care treatment since 
the 1990s (6). This treatment was not very effective and had multiple side effects. Since 
2011, the development of targeted direct acting antiviral (DAA) therapy has revolutionized 
the treatment of HCV infection (9, 115) . The interferon free combinations introduced in 
2014 cure chronic HCV infection in > 95 % of patients, regardless of viral genotype, fibrosis 
stage or co-infection with HIV (116) . Cure, meaning sustained viral response (SVR), is 
defined as negative HCV-RNA 24 weeks after cessation of treatment. The new treatment has 
almost no or only mild side effects. DAAs target three proteins in the HCV life cycle: 
NS3/NS4A protease, NS5B polymerase and NS5A protein (Table 2).  
Different combinations of DAAs are used for different genotypes and patient groups and new 
treatment combinations are approved frequently (Table 2). Recently pangenotypic treatments 
have been developed (117). The DAA treatment usually consists of 1-3 oral pills per day for 
8-12 weeks in most cases and no longer than 24 weeks. This is in contrast to the older 
interferon based treatment, which had to be given as injections for up to 12 months.  
DAA treatment has been shown to be as effective and safe in children as in adults and was 
recently made available for children with chronic HCV infection above 12 years of age in EU 
and US (118-120). Several pediatric DAA studies are ongoing. DAA treatment has 
revolutionized the management of chronic HCV infection and changed the view on this 
disease from hard- to easy- to treat. The treatment is still very expensive and at the moment 
only few countries can afford to treat all patients with chronic HCV. Treatment uptake is low 
even in some high-income countries. In Sweden only patients (including children) with 
fibrosis score F2-F4 were recommended DAA treatment from 2014. However, with reduction 
in prices the latest Swedish recommendations favour treatment for all chronically infected 
(121). In many low-income countries, IFN based treatment is still the most common option, 
however generic DAA treatment to a lower cost has recently become available, in fact also 
for children (122). Efforts have been made to develop a vaccine against HCV, but there is yet 
today no such vaccine available. The effectiveness of DAAs has encouraged WHO and many 
countries to set up goals to eliminating the disease as a major health threat by 2030 (1). 
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Table 2. Available DAA treatment regimens in Europe by February 2018. DAA treatment 
should always involve a combination of at least two substances. Ribavirin can be added to all 
the combinations. 
 
 
 
NS5B polymerase inhibitor NS5A inhibitor NS3/4A protease inhibitor Genotype 
Sofosbuvir   1-6 
  Simeprevir 1,4 
 Daclatasvir  1-4 
 
Sofosbuvir1 
 
Ledipasvir1  1, 4 
 
Sofosbuvir2 
 
Velpatasvir2  1-6 
 Ombitasvir Paritaprevir (+/- Ritonavir) 1,4 
Dasabuvir   1 
 Elbasvir
3 Grazoprevir3 1,4 
 Pibrentasvir
4 Glekaprevir4 1-6 
Sofosbuvir5 Velpatasvir
5 Voxilaprevir5 1-6 
 
 
 
1 Fixed combination Sofosbuvir + Ledipasvir; Harvoni® 
2 Fixed combination Sofosbuvir + Velpatasvir; Epclusa® 
3 Fixed combination Grazoprevir + Elbasvir; Zepatier® 
4 Fixed combination Pibrentasvir + Glekaprevir; Maviret® 
5 Fixed combination Sofosbuvir + Velpatasvir + Voxilaprevir; Vosevi® 
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3( AIMS(
 
The overall aim of this thesis was to study epidemiological and immunological aspects of 
hepatitis C virus exposure early in life.  
 
Specific aims were: 
•, To investigate the role of neonatal blood transfusions as the transmission route of 
HCV infection in adult patients and to describe the natural course in those presumably 
infected by neonatal blood transfusion (paper I). 
 
•, To investigate the prevalence of HCV infection and previous HCV testing among 
childhood cancer survivors in Stockholm and to screen those previously untested 
(paper II). 
 
•, To investigate if IL28B genotype was associated with risk of vertical transmission of 
HCV infection (paper III). 
 
•, To study the presence and relevance of  HCV specific T cell responses in children 
born of mothers with chronic HCV infection (paper IV). 
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4( MATERIALS(AND(METHODS(
4.1( PATIENTS(AND(STUDY(DESIGN(
Three different study populations were used. Paper III and IV included partly the same group 
of patients, where the Stockholm cohort was the same in both papers but in paper III patient 
cohorts from Örebro and St Petersburg were added. 
 
4.1.1( Paper(I(
In this retrospective register-based cohort study, 255 adult patients born 1960-1975 with 
chronic hepatitis C virus infection and followed at Karolinska University hospital, 
Stockholm, Sweden were contacted by mail and invited to participate. In total, 230 patients 
were eligible for the study (Fig. 4). Maternity and/or neonatal medical records of all included 
patients were studied for the occurrence of a neonatal blood transfusion. Patients without a 
documented referral to a neonatal ward were considered not transfused since blood 
transfusions are given at neonatal units. The prevalence of previous neonatal blood 
transfusion was then estimated and compared between the patients with known versus 
unknown HCV transmission route. Clinical data on the natural course of HCV infection in 
patients transfused as neonates were collected from the hospital medical record system. 
Available liver biopsy specimens were re-evaluated by a pathologist who had no previous 
knowledge of the patients.  
 
Figure 4.  All 255 patients eligible for study I, subdivided as participants, decliners, and 
nonresponders. *Maternity records collected and studied. †Neonatal records collected and studied. 
(n)"="number of patients with unknown transmission route according to data in medical records.  
Chronic(Hepatitis(C
255#
Agreed(to(participate*
70#(35)
Declined(Participation
25
Did(not(respond(to(any(
letter†
160#(63)
Not(transfused*†
66#(32)
Blood(transfusion*†
4#(3)
Exchange(transfusion*†
2#(1)
Single(blood(transfusion*†
2#(2)
Not(transfused†
160#(63)
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4.1.2( Paper(II(
This was a combined retrospective register-based and prospective screening study of adult 
childhood cancer survivors treated for malignancy in Stockholm before 1992. First, we 
investigated the prevalence of HCV infection and previous anti-HCV testing. Next, we 
screened the remaining and untested cohort for HCV infection. A clinical pediatric oncology 
register was used, containing 2171 patients who had undergone investigation and/or treatment 
at the Pediatric Oncology department at Karolinska University hospital, Stockholm, Sweden 
from 1921 to 1991. Patients with benign diagnoses, age above 18 years at initiation of 
therapy, deceased before 1992 and patients registered without a personal identification 
number were excluded. Patients in the included remaining cohort (n = 686) were then 
checked for existing notification of hepatitis C infection in the national register of hepatitis C 
cases at the Public Health Agency. The degree of liver disease and antiviral treatment 
outcome of patients diagnosed with HCV infection was analyzed. To investigate the 
prevalence of previous HCV testing, medical records as well as laboratory registers were 
analyzed for documented anti-HCV test.  
In the second prospective part of the study, a cohort of 231 patients living in Stockholm 
County without a traceable and documented anti-HCV test were contacted by letters and 
invited to participate in the HCV screening study (Fig.7). Patients, who choose to participate 
in screening by returned written informed consent, were offered a blood test for anti-HCV 
free of charge at the nearest primary health care center. Two reminding letters were sent.  
Analysis was made of age, gender, malignancy diagnosis, time of treatment and HCV testing 
as well as results of anti-HCV screening.  
 
4.1.3( Paper(III(
This was a cross-sectional study of the Stockholm cohort used in paper IV, with the addition 
of two new cohorts from Örebro and St Petersburg. Patients were enrolled from three 
different pediatric departments at Karolinska University Hospital in Stockholm, Örebro 
University Hospital in Örebro, Sweden and Science Research Institute of Children’s 
infections in Saint Petersburg, Russia. In total 59 HCV-RNA positive/HIV negative mothers 
and 123 children born to HCV-infected/HIV negative mothers were included and their stored 
plasma samples were analyzed for IL28B polymorphism (SNP rs12979860) and classified by 
the IL28B genotype (C/C, C/T and T/T) as well as by viral genotype. The 59 mothers gave 
birth to 70 children who were included together with another cross-sectional cohort of 53 
children of HCV-RNA positive mothers where the maternal IL28B status was unknown (Fig. 
5). Out of the included 123 children, 47 were vertically infected and 76 HCV exposed but 
uninfected. The patients from the Stockholm cohort were the same as in paper IV with the 
addition of 10 exposed but uninfected children and 5 infected mothers. Exposed children 
were enrolled when routinely tested for HCV antibodies at the age of 18 months. The 47 
HCV infected children were enrolled in the study as patients followed at the pediatric 
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departments. Uninfected children were considered exposed to their mothers’ viral genotype. 
All children were tested for HCV antibodies at the age of around 18 months, i.e. when 
passive maternal antibodies had disappeared.  
The two groups of infected and uninfected children were compared with respect to the 
genetic variant of IL28B as well as by HCV viral genotype (HCV-gt)(Fig. 5A). The 59 
mothers were also divided into two groups and labelled as transmitting or non-transmitting 
and compared with regard to IL28B genotype and HCV-gt (Fig. 5B). Mothers who gave birth 
to siblings where one was infected and the other one not, were considered as transmitting 
mothers.   
A 
  
B  
 
Figure 5. All patients included from the three centers and subdivided by infectious status and 
IL28B genotype, N(%). IL28B = Interleukin 28B. A) All included children B) All included 
mothers 
70#(57)
St#Petersburg
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76 (62)
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47 (38)
Infected
12#(16)
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IL28B#T/T
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17 (36)
IL28B#С/C
34#(58)
St#Petersburg
20#(34)
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4.1.4( Paper(IV(
This was a combined prospective and cross-sectional cohort study. Included in the study was 
one group of 15 HCV-RNA positive/HIV-negative mothers and their 21 children followed 
prospectively from birth, of whom two became infected, as well as a cross-sectional group of 
13 uninfected children born to chronically HCV infected mothers and another cross-sectional 
group of 7 vertically HCV infected children/adolescents (Fig. 6). The cross-sectional groups 
of patients were added in order to increase the study population and to obtain study subjects 
of different ages. As adult and pediatric control groups, blood from 10 anti-HCV negative 
adult blood donors and cord blood from 10 newborns (born of anti-HCV negative mothers) 
were used. Pregnant HCV infected women were included at a maternity clinic specialized in 
blood borne infections in Stockholm. The cross-sectional group of uninfected children was 
enrolled when routinely tested for HCV antibodies at the age of 18 months. All participating 
mothers and children were tested at the Department of Pediatrics, Karolinska University 
Hospital in Stockholm. 
 
Figure 6. The included mothers and children from both prospective and cross-sectional cohorts in 
study IV. 
 
Blood samples from the mothers were collected at one time point within 0-7 months post 
partum. In the prospectively studied group, blood samples from their children were collected 
consecutively at one, two or three time points at around 0, 6 and 18 months of age. In the 
cross-sectional groups, blood samples from the uninfected group of 13 children were 
collected at one time point between 18-27 months of age and samples from the group of 7 
HCV vertically infected children were collected at one time point at study inclusion. Vertical 
infection was defined by the detection of two positive HCV-RNA blood tests with the same 
viral genotype as the mother within a period of at least 6 months. All blood samples were 
analyzed within 24 hours after venous puncture, using peripheral blood mononuclear cells 
(PBMC) isolated from fresh whole blood. 
15
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19
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Exposed Children
21
HCV&Exposed
Children
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4.2( (METHODS(
4.2.1( Register(analyses(and(medical(record(reviews(
Paper I. The patient register used in paper I was a clinical register of 255 adult patients born 
1965-75 with chronic hepatitis C and registered as patients at the department of Infectious 
Diseases, Karolinska University hospital, Stockholm in 2005 (when the study was initiated). 
Their neonatal and maternity records that were mainly handwritten (not digitalized) were 
ordered from medical records archives from different parts of Sweden depending on 
residency at birth. Medical records, from the hospital’s computerized record system “Take 
Care”, were studied for the documented putative source of HCV infection at diagnosis as well 
as the clinical course of HCV infection.  
Paper II. The clinical pediatric oncology register used in this study was originally 
handwritten and subsequently transformed into digital form. It contained pediatric patients 
that had been investigated and/or treated for any form of oncological diagnosis at Karolinska 
university hospital, Stockholm. It included also benign diagnoses and investigated patients 
with suspected but not confirmed diagnoses. The small size of the register and the fact that 
the majority of patients it included were still alive made us hypothesize that it probably only 
contained patients who survived treatment passed a certain, but unknown, time point. 
Medical records, from the hospital’s computerized record system “Take Care”, were studied 
for documented previous anti-HCV test results. Additionally, scanned paper records in “Take 
Care” were analyzed. When tests were not to be found in the medical record system we then 
analyzed three different forms of previous (i.e. no longer in use) virological laboratory 
systems for occurrence of anti-HCV test in each patient. The personal ID numbers of each 
patient in the oncology register was crosschecked with the Swedish national public health 
care register of notified HCV infected patients in order to investigate how many that already 
had a documented HCV infection. 
 
4.2.2( Virological(analyses((paper(II,(III,(IV)(
Anti-HCV.  
All anti-HCV analyses were performed at clinical routine laboratories. At Karolinska 
University Hospital, Division of Clinical Microbiology, the analyses were performed by third 
generation enzyme immuno assay (ARCHITECT Anti-HCV, Abbott, Wiesbaden, Germany). 
HCV-RNA assays.  
All HCV-RNA quantification analyses were performed at clinical routine laboratories. At 
Karolinska University Hospital, Division of Clinical Microbiology, the analyses were 
performed by TaqMan real-time PCR (Roche Molecular Diagnostics, Branchburg, NJ, USA) 
with a detection limit of 15 IU/ml. HCV genotyping was performed with a line probe assay 
(Inno-LiPA HCV II, Innogenetics NV, Gent, Belgium). 
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4.2.3( Immunological(analyses((paper(III(and(IV)(
IL28B assay.  
DNA from patients’ stored plasma samples was genotyped for IL28B rs12979860 
polymorphism with TaqMan SNP genotyping assay (Applied Biosystems Inc, Foster City, 
CA, USA), using the ABI 7500 Fast equipment. All TaqMan probes and primers were 
designed and synthesised by Applied Biosystems Inc. Automated allele calling was 
performed using SDS software from Applied Biosystems. The primers and probes used were: 
rs12979860 Forward primer: 5´GCCTGTCGTGTACTGAACCA3´, Reverse primer: 
5´GCGCGGAGTGCAATTCAAC3´, Vic probe: 5´TGGTTCGCGCCTTC3´, Fam probe: 
5´CTGGTTCACGCCTTC3´. Human genomic DNA was purified from 200-500 µl of plasma 
and preformed according to manufacturer’s instructions using the QIAamp DNA Mini kit 
(Qiagen, Hilden, Germany), except for one change in the elution step, elution was done using 
25 µl elution-buffer. The result was presented as IL28B CC, C/T or TT genotype.  
Isolation of PBMC.  
Peripheral Blood Mononuclear Cells (PBMC) were isolated from fresh whole blood (2-8 ml) 
using a Ficoll gradient.  
Recombinant proteins and peptides.  
Recombinant HCV proteins were pooled as NS3 and NS4 protein (3 µg/mL each), 
recombinant Core protein (3 µg/mL), recombinant NS5A and NS5B protein (3 µg/mL each), 
or a mixture of all proteins (rNS3, rNS4, rCore, rNS5A, rNS5B (3 µg/mL each)). Genotype-
specific peptides covering NS3 were used and distributed in two pools with 0.6 µg/mL of 
each peptide (6 NS3 MHC class I peptides for genotype 1 and 3 each, and 16 NS3 MHC class 
II peptides for genotype 1 and 3 each). Peptides were purchased from Sigma–Aldrich (St. 
Louis, MO). In patients infected with or exposed to HCV genotype 2 and 4 we used peptides 
corresponding to genotype 3, since recombinant peptides for those genotypes were not 
available. All recombinant HCV proteins (Core, NS3, NS4, NS5A and NS5B) were 
purchased from Mikrogen (Neuried, Germany), and Concanavalin A from Sigma-Aldrich.  
ELISpot assay.  
The human IFN-γ Enzyme linked Immunospot (ELISpot) assay was performed according to 
the manufacturer’s instruction (MabTech, Nacka Strand, Sweden) with 
0.2 × 106 PBMCs/well (123). Plates were incubated for 48 hours in the presence of 
recombinant HCV proteins (3 µg/mL each), NS3 peptides (MCH class I and II, 0.6 µg/mL of 
each peptide), medium as negative control, and Concanavalin (ConA, 2 µg/mL) as positive 
control. Each stimulation was done in duplicates, or when enough cells were available, in 
triplicates and spot counts were calculated as mean spot forming units (SFU)/106 cells. A 
positive cut-off value for adults and children (< 2 years old) was calculated from the ELISpot 
results of the adult and pediatric negative control groups respectively and defined as mean 
SFU/106 PBMC in test wells - negative control wells + 3 x SD. The cut-off was set at > 46 
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SFU/106 cells for adults and > 31 SFU/106 cells for children below the age of two years. The 
cut-off value of > 46 SFU/106 PBMC was used for children older than 2 years (124). The 
positive control, ConA was > 150 SFUs/106 PBMC in all samples included in the analysis 
proving the viability of the cells. The number of spots was counted using the AID ELISpot 
reader system Version 7.0 (Autoimmun Diagnostika, Strassberg, Germany). 
3H thymidine incorporation assay.  
The HCV specific T cell proliferation was analyzed using a 3H thymidine incorporation 
assay. Cells were cultivated for 72 hours in 96-well U-bottom plates (Nunc) in complete cell 
culture medium (Sigma-Aldrich) in triplicates with 3 × 105 cells per well. After 72 h of 
cultivation, 3H-thymidine (Perkin Elmer) was added at a final concentration of 0.1 Ci/ml. 
Twenty hours later cells were harvested and 3H activity was measured by means of liquid 
scintillation counting (TRILUX 1450 MicroBeta counter). From the counts per minute (cpm) 
values, the stimulation index (SI) was calculated as a ratio of stimulated/unstimulated. A 
positive cut-off SI was calculated from the adult control group and defined as mean SI + 3 x 
SD and set at SI >2.80. Since the positive cut-off level is calculated from a quotient there was 
no need for a specific child control group. The adult control group was then used as 
comparison for both mothers and children. 
NS3 IgG antibody detection.  
The specific NS3 antibody titer from human plasma was determined by using a specific solid 
phase enzyme-linked immunosorbent (ELISA) assay (123). Recombinant NS3 (1 µg/mL) in 
50 mM sodium carbonate buffer pH 9.6 was passively adsorbed into 96-well flat-bottom 
plates overnight at 4 °C. Patient plasma was serially titrated six-fold with a 1:60 starting 
dilution and then incubated on the plates for 1 h. Bound antibodies were detected by anti-
human IgG-alkaline phosphatase antibody and p-nitrophenyl phosphate substrate tablets 
(both from Sigma-Aldrich, St. Louis, MO, USA). Antibody titers were determined as the last 
serum dilution giving an optical density at 405 nm of three times the optical density at the 
same dilution of plasma from a patient who has never been infected with HCV. 
 
4.2.4( Statistical(analyses(
All statistical analyses assumed a two-sided significance level of 0.05. In the two 
epidemiological studies (I and II) the exact confidence interval (CI) was calculated for a 
binomial distribution. Bivariate analysis to compare proportions between independent groups 
was performed using Fisher’s exact test in all studies. In study II, McNemars test was used 
for the analysis of the effectiveness of the two dependent screening methods. Analysis of 
non-parametrical data (Spot forming units and proliferation indexes for each patient) in study 
IV was performed using Mann-Whitney U test. Median regression analysis was used in study 
IV to investigate relationships between predictors and outcome.  
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Statistical analysis was performed with computer software Statistica (StatSoft, Tulsa, OK) in 
study I and with GraphPad Prism software version 6.04 and 7 (GraphPad Software, San 
Diego, CA) in study III-IV and STATA 13 (Stata Corporation, College Station, TX) software 
in study II and IV. 
 
4.2.5( Ethics(
All studies were performed according to the Helsinki declaration and were approved by the 
regional Ethics Committee. 
Paper I: Dnr 269/03 + 2011/1098-32 + 2013/559-32 
Paper II: Dnr 2011/1372-31/3 + 2015/1141-32 + 2017/1195-31/2 
Paper III and IV: Dnr 2008/1442-31 + 2010/1263-32 + 2011/614-32 + 2012/74-32 + 
2015/0081-32 
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5( RESULTS(AND(DISCUSSION(
5.1( BLOOD(TRANSFUSIONS(AND(THE(RISK(OF(CHRONIC(HCV(INFECTION(
(PAPER(I(AND(II)(
In the first two studies (I and II) blood transfusion before 1992 as transmission route for 
chronic HCV infection in two different pediatric risk groups was explored.  
 
5.1.1( Blood(transfusion(in(the(neonatal(period(and(the(risk(of(chronic(HCV(
infection((paper(I)(
In study I we investigated if blood transfusion in the neonatal period could explain the 
transmission route in adult patients born 1960-75 with chronic HCV infection. Out of 230 
patients eligible for the study, 98 (43 %) had unknown transmission route and 128 (56 %) had 
a documented known transmission route according to data in medical records (Fig 4). In four 
patients the medical records were unavailable for review. The median duration of hepatitis C 
infection was 32.5 years (range, 27-42 years).  
 
The main findings of this study were: 
I., Four out of 230 (1.7 %; 95 % CI, 0.5 % - 4.4 %) patients with chronic HCV infection 
had received blood product transfusion in the neonatal period. Two of them had 
undergone exchange transfusions.  
 
II., None of these four patients were aware of their history of previous neonatal blood 
transfusions at the time of diagnosis, however one patient was soon after diagnosis 
found to be transfused as a neonate and was therefore regarded as a patient with 
known transmission route. 
 
III., There was no significant difference in the proportion of neonatal blood transfusion 
recipients between those registered as having unknown (3/98, 3 %) and known 
(1/128, 0.8 %) transmission route (p = 0.4).  
 
IV., Liver biopsies were reevaluated in three of the four patients. One of them had severe 
inflammation (grade 3 of 4) and liver cirrhosis (Stage IV of IV). The two other 
patients had mild signs of inflammation and fibrosis. Three of the four patients, 
including the one with cirrhosis, were successfully treated for hepatitis C. 
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5.1.2( Transfusion(transmitted(hepatitis(C(in(childhood(cancer(survivors(
(paper(II)(
In study II we first investigated the prevalence of HCV testing and HCV infection in a group 
of 686 patients treated for childhood cancer in Stockholm before 1992. Out of the 686 
patients, 127 had a traceable anti-HCV test. An unknown part of the cohort might have been 
tested outside Stockholm County and those tests were not possible to trace. The time point of 
testing was analyzed in order to find out how many had been tested during the national 
Swedish screening campaign in 2007-2010. Ten patients out of the total cohort were HCV-
RNA positive with transfusion transmission as the most likely source of infection (Fig. 7).  
In the second part of the study we actively traced and screened a sub-cohort of 231 
presumably untested patients living in Stockholm County for HCV infection, of whom 136 
accepted participation in the study. Of those, 75 took the test and 1 was found to be HCV 
infected (Fig. 7). In all, 11 out of 233 (5 %) tested individuals in the total cohort were found 
to be HCV infected. 
 
The main findings of this study were: 
I., The overall prevalence of chronic HCV infection among the tested childhood cancer 
survivors was 5 %, which is 10 times higher than the national prevalence of 0.5 % 
(RR=10).  
  
II., Only 12 % of the Stockholm cohort were tested during the screening campaign in 
2007-10.  
 
III., The test uptake in the active tracing screening within this study was far better than in 
the national general screening campaign (39 % vs 12 %) (p< 0.001). 
 
IV., In spite of long duration of HCV infection and the possible additive effect of 
chemotherapy, the HCV infected patients had mild to moderate signs of liver 
disease. The majority underwent successful antiviral treatment. 
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Figure 7. All included patients and testing outcome in the study. Figures with rounded 
corners represent part 2 of the study (the active tracing screening). HCV= Hepatitis C virus 
 
5.1.3( High(prevalence(of(chronic(hepatitis(C(virus(infection(in(pediatric(
multitransfused(risk(groups(
Several studies have shown a high HCV prevalence among pediatric transfusion recipients in 
certain risk groups, for example children treated for childhood cancer, hemophilia and 
prematurity as well as children who underwent open-heart surgery or dialysis before 1992 
(when blood donor screening was introduced) (20, 24, 28, 125, 126). Our results in study II 
are in line with previous findings of childhood cancer survivors where the HCV prevalence 
ranges between 6-40 %, depending on which malignancies that are included (25, 28). We 
found a relatively high prevalence of 5 % chronic HCV infection among childhood cancer 
survivors in Stockholm, compared to the national anti-HCV prevalence of around 0.5 %. The 
HCV prevalence among patients transfused at neonatal wards varies between 0.5-42 % 
depending on location and time period studied (18, 20). In study I we found a prevalence of 
1.7 % neonatal blood transfusion recipients in a group of adult patients with chronic HCV 
infection.  
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5.1.4( Low(awareness(of(previous(blood(transfusions(in(pediatric(risk(groups(
Adult patients who received blood transfusions during childhood are often unaware of their 
transfusion history (127). The transfusion awareness is particularly low in individuals 
transfused in the neonatal period (19, 21). Furthermore, it has been shown that only 50 % of 
childhood cancer survivors recall previous blood transfusions during cancer treatment (23). 
The low awareness of transfusions given in childhood contributes to disregard of public HCV 
screening campaigns targeted at transfusion recipients, since they do not consider themselves 
as part of this risk group. If not actively traced, this large population of individuals at risk 
might never be tested or diagnosed. 
 
5.1.5( Natural(course(and(treatment(outcome(of(transfusion(transmitted(
chronic(hepatitis(C(virus(infection(acquired(during(childhood(
Individuals who were HCV infected by blood transfusions given in childhood have often a 
long duration of HCV infection at diagnosis. It is well known that duration of infection 
contributes to increased risk of developing HCV related liver cirrhosis (71). However, most 
studies of transfusion transmitted HCV infection acquired during childhood show that the 
majority has mild signs of liver disease, slow progression of liver fibrosis and a high rate of 
spontaneous clearance (24, 109). Apart from young age at infection, lower degree of 
comorbidity factors in children, such as alcohol intake, drugs and other diseases might 
explain this slow progression (71). A more severe liver disease, including advanced cirrhosis 
needing liver transplantation, has been described already during adolescence (21, 102). In 
study I we found that 1 out of 4 patients transfused as neonates had established liver cirrhosis 
at the time of diagnosis, after 27 years of infection. This patient had no other risk factors of 
progressive liver disease apart from the long duration of infection.  
In our study (paper II) all HCV infected patients, transfused during treatment of childhood 
cancer, had mild to moderate liver fibrosis, albeit the long duration of infection and previous 
chemo- and immunosuppressive therapy, which has been shown to increase the risk of liver 
fibrosis (27). Our results are in line with some of the previous long-term studies on childhood 
cancer survivors (26, 29, 128), however Castellino et al. described a high prevalence of 13 % 
liver cirrhosis already after 12 years of median infection duration (27). 
 
5.1.6( Hepatitis(C(screening(of(pediatric(transfusion(recipients(
In the era of new highly effective and safe DAA treatment, the issue of finding the still 
undiagnosed has become crucial to achieve the goal of HCV eradication. The question of 
whom to screen and how to do it has drawn big attention. Several attempts to screen 
transfusion recipients in general look-back studies have been carried out worldwide (127, 
129). The choice of screening method is a matter of time and money. Big national public 
screening campaigns in form of posters and public media advertisement, such as the Swedish 
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national screening campaign in 2007-2010, seem to be comparatively cheap and time saving, 
however they may fail to reach pediatric risk groups that do not recall previous blood 
transfusions (17). General national screening campaigns have in fact been shown to be the 
least cost-effective (130). In order to reach the pediatric risk groups (i.e. patients treated for 
prematurity, cancer or open-heart surgery) direct tracing screening is a more effective 
screening method, which we showed in paper II. We found that non-active tracing screening 
reached 12 % of patients possible to screen of whom 5 % were HCV positive and the active 
tracing screening reached 39 % (p < 0.001) of whom 1 % were HCV positive. The finding, 
that test uptake is better in active tracing screening, is supported by a previous meta-analysis 
of different screening methods (131) (Fig. 8).  
 
Figure 8. Forest plots comparing targeted HCV testing interventions versus no targeted testing 
intervention by type of targeted testing: outcome; HCV antibody cases detected. From Targeted 
Hepatitis C antibody testing intervention: a systematic review and meta-analysis. Aspinal et al. 
European Journal of Epidemiology 2014. Reprinted by permission from Springer Nature.  
 
Patients transfused as neonates are probably least aware of their transfusion history, and for 
this group active tracing screening is particularly recommended. In two Swedish Counties 
(Halland and Västra Götaland), previous attempts to actively trace and test pediatric risk 
groups (as part of the national screening campaign) were made with a surprisingly low test 
frequency (46 % and 11 % respectively) (17). In Halland none of the 264 tested pediatric 
transfusion recipients were anti-HCV positive and in Västra Götaland 18 out of 479 tested 
were anti-HCV positive (5 previous heart surgery, 3 previous prematurity care and 10 
childhood cancer survivors), of whom 14 were HCV-RNA positive (3, 3 and 8 respectively) 
(15, 17). Patients treated for prematurity were not possible to actively trace and test due to 
legal confidentiality issues and the ones found in the screening campaign had participated in 
the general public screening campaign. Another way to trace transfusion recipients is by so 
called targeted look-back studies, where tracing originates from one HCV-positive blood 
donor and its recipients (22, 132, 133). This option is the most time consuming one but might 
be highly effective since all recipients have been exposed to contaminated blood. 
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5.2( INVESTIGATION(OF(IMMUNOLOGICAL(FACTORS(IN(VERTICAL(
TRANSMISSION(OF(HCV(INFECTION((PAPER(III(AND(IV)(
In study III and IV the impact of certain immunological factors on vertical transmission of 
HCV (HCV-VT) were explored. 
 
5.2.1( Lack(of(association(between(IL28B(genotype(and(vertical(transmission(
of(hepatitis(C(virus((paper(III)(
In study III the impact of IL28B genotype on the risk of vertical HCV transmission was 
investigated. We included 59 mothers with chronic HCV infection and 123 children (47 
infected and 76 uninfected) born of HCV infected mothers. IL28B genotype was analyzed in 
both groups and sorted as C/C, C/T and T/T (Fig. 5). The proportion of children with 
genotype C/C was the same in the vertically infected (36 %, 17/47) and the exposed 
uninfected children (38 %, 29/76) (Fig. 5 and Table 3 and 4).  
 
The main findings of this study were:  
 
I., Neither children’s nor mother’s IL28B genotype was associated with vertical 
transmission of HCV infection. No difference was seen when stratifying for viral 
genotype.  
 
II., The IL28B genotype C/C, which has been shown to be favorable in other settings, 
was not protective of HCV-VT.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
Table 3. IL28B gt distribution in children                
  
IL28 genotype distribution among vertically infected vs. uninfected but exposed children, displayed as 
C/C or non C/C (C/T and T/T combined) for exposure to HCV genotype 1(1a+1b), 2 (2a+2b), 3 (3a + 
3b), 4 and unknown genotype.  
 
Table 4. IL28B gt distribution in mothers 
 
IL28 genotype distribution among transmitting mothers vs. non-transmitting mothers, displayed as 
C/C or non C/C (C/T and T/T combined) for exposure to HCV genotype 1 (1a+1b), 2 (2a+2b), 3 (3a 
+ 3b), 4 and unknown genotype.  
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5.2.2( HCV(specific(T(cell(responses(detected(in(exposed(infected,(and(
exposed(but(uninfected(newborn(children((paper(IV)(
In Study IV we investigated HCV specific T cell reactivity in children exposed to maternal 
HCV during pregnancy and delivery. All participating subjects are shown in Figure 8. In this 
study we showed that an HCV specific T cell response, defined as positive IFNγ response 
and/or HCV specific T cell proliferation, could be detected in in vitro in 73 % (11/15) of the 
HCV infected mothers, 67 % (6/9) of the vertically infected children, 56 % (18/32) of the 
exposed but uninfected children and in 10 % and 20 % of the control groups (Fig. 9).  
 
The main findings of this study were: 
I., The two groups of HCV exposed children both had a significantly higher proportion 
of HCV specific T cell responders compared to pediatric controls (p = 0.01 and p = 
0.02).  
 
II., We detected HCV specific CMI (cell mediated immune) responses in uninfected 
children of HCV infected mothers already in the newborn period, suggesting a pre- or 
perinatal exposure to viral antigens. 
 
III., The frequency and magnitude of the CMI response in the exposed but uninfected 
children was similar to that detected in vertically infected children and persisted up to 
at least two years of age.  
 
IV., The immune responses were mainly HCV-specific IFNγ recall responses to HCV 
antigens and not always linked to HCV specific T cell proliferation. 
 
V., A significantly higher number of children in both the uninfected/exposed group and 
the vertically infected group had a broad IFNγ response towards multiple HCV 
antigen pools compared to the child controls (p = 0.04 and p = 0.02 respectively). 
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Figure 9. The proportion of overall HCV specific T cell responders in the groups of patients (A), the 
proportion of IFNγ ELISpot responders (B), the cumulative IFNγ response (expressed as mean spot 
forming units (SFU)/106 cells, error bars representing median+IQR (interquartile range) (C) and the 
positive IFNγ response to the number of different antigen pools (D). Cut-off for a positive IFNγ 
response > 46 SFU/106 cells for patients > 2 years and > 31 SFU/106 cells for children < 2 years. 
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5.2.3( The(impact(of(IL28B(genotype(on(vertical(HCV(transmission(and(
spontaneous(viral(clearance((paper(III)(
Single nucleotide polymorphism (SNP) near the gene for IL28B (SNP rs12979860) was in 
2009 found to be of importance to IFN based treatment outcome (64). The favorable IL28B 
genotype C/C was demonstrated to double the SVR rate in IFN based treatment (64). The 
C/C allele was also found to be three times as common in adults who spontaneously cleared 
HCV infection (65). IL28B genotype was later renamed Interferon-lamba-3 (IFNλ3), which 
is a more correct term, but for clearance reasons the term IL28B genotype is used herein since 
it was the term used in paper III. In paper III we investigated if IL28B genotype was 
associated with the risk of HCV-VT. We did not find such an association. We concluded that 
the, in other ways, favorable genotype C/C was not protective of HCV-VT. To the best of our 
knowledge, there is only one previous study similar to ours by Ruiz-Extremera et al., 
investigating the possible relationship between IL28B genotype and HCV-VT in 128 
children. They came to the same conclusion as we did, i.e. they found no association between 
those two factors. However, they did find a correlation between IL28B C/C genotype and 
spontaneous clearance of HCV genotype 1, where 83 % of children with genotype C/C 
cleared the infection compared to 22 % of those with genotype non-C/C (110). This finding 
has been confirmed in other subsequent pediatric studies, which also conclude the same 
correlation independent of viral genotype (77, 107). In the largest multicenter, cross-sectional 
study by Indolfi et al., 177 children were included and spontaneous clearance was 2 times 
more likely in those with IL28B genotype C/C (79). The exact molecular mechanisms 
underlying the effect of IL28B genotype on spontaneous clearance and IFN treatment 
outcome remain unclear. IL28B induces production of IFNλ3 via the JAK-STAT pathway 
and presence of the unfavorable T allele results in less IFNλ3 expression and impaired host 
antiviral defense mechanisms (134). 
 
5.2.4( Other(host(immune(factors(and(vertical(transmission(
Since clinical factors cannot explain why HCV-VT occurs in a few but not in others, various 
host immunological factors have been hypothesized to play a role. Among factors studied are 
HLA-types, neutralizing antibodies and NK-cells. HLA-mismatch between a mother and her 
child has been described as favorable with regard to vertical viral transmission, since the 
child´s immune cells has better chance to recognize and kill the virus if its immune system is 
different from its mother’s. HLA-mismatch and the presence of certain HLA-types have been 
shown to reduce the rate of vertical transmission of HCV-VT, but the findings are 
contradicting (43, 135, 136). It has been demonstrated that maternal neutralizing HCV-
antibodies are not protective of HCV-VT (137, 138). NK-cells might be a more important 
player in HCV-VT than previously thought, as altered phenotype and number of NK cells has 
been shown to play a role in spontaneous clearance of vertically transmitted HCV infection 
(139). Different types of NK cell receptors; KIRs (Killer-cell immunoglobulin-like receptor) 
have recently been described to be associated with the rate of HCV-VT (136). 
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5.2.5( HCV(specific(T(cell(responses(in(children(of(infected(mothers(((((((
(paper(IV)(
In study IV we investigated HCV specific T cell responses in children born of HCV infected 
mothers. The proportion of overall T responders (defined as positive IFNγ response and/or T 
cell proliferation) was 73 % in the mothers, 67 % in the vertically infected children, 56 % in 
the uninfected/exposed children, 20 % in adult controls and 10 % in pediatric controls (Fig. 
9A). The two groups of prenatally exposed children both had a significantly higher 
proportion of responders compared to pediatric controls (p < 0.05). The finding that the 
proportion of T cell responders was almost as high among uninfected children as in vertically 
infected ones is in line with the results from Della Bella et al., reporting 72 % (18/25) HCV 
specific T cell responders in vertically exposed/uninfected children, 67 % (2/3) of vertically 
infected children and 52 % (12/23) of infected mothers. However, their cohort included 
children age 1-4 years and thus did not give any information on the events early after birth 
(44). They concluded that this CMI response might be protective and contribute to the low 
rate of vertical HCV transmission. In a study by El-Kamary et al. a lower proportion of 14 % 
T cell responders was found among exposed/uninfected children (70). Babik et al. 
investigated the immune response to HCV exposure in utero in cord blood of children born of 
HCV infected mothers and found signs of general immune suppression compared to 
unexposed controls. On the contrary, exposed neonates had increased capacity of IFNγ 
production but no HCV specific T cell responses were detected (140). Studies on other HCV 
exposed but uninfected populations, such as household members, spouses, siblings and health 
care workers have reported similar findings with high proportions of HCV specific T cell 
responders (141-144). 
The CMI response found in our study was mainly an IFNγ recall response and not always 
linked to T cell proliferation. On the contrary, Della Bella et al. found mainly a proliferative 
response whereas the IFNγ response was not significantly stronger than controls, however, 
they used a different method to analyze IFNγ production (43). One reason for this difference 
might be the choice of laboratory method to analyze HCV specific T cell proliferation. We 
used 3H-thymidine incorporation, a method considered golden standard, in which an isotope 
is incorporated within diving (proliferating) T cells upon stimulation of viral antigens in vitro. 
Della Bella et al used BrDU (-5-bromo-2′-deoxyuridine) incorporation flow cytometry as 
proliferation method. Both methods are described to correlate fairly well in terms of 
proliferation results (145-147). However, some drawbacks are described for 3H-thymidine 
incorporation, attributed to the adverse effect of β-radiation on mitotic cells (148). Another 
explanation might be the younger age of our study cohort, where we included some children 
already from 3 days of age compared to from 1 year of age in the other study. Reduced T cell 
proliferation and cytokine production in response to in vitro stimulation of other viral 
antigens has been reported in neonates (149). Since the immune system of newborns is 
considered immature, we calculated specific cut-off values for IFNγ ELISpot in children 
younger than 2 years of age based on the mean spot-forming unit (SFU) of the cord blood 
controls + 3 SD. The cut-off SFU for children < 2 years was set at 31/106 cells and at 46/106 
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cells for adults and children > 2 years (based on the results of the adult control group). Lack 
of standardized cut-off ELISpot SFU values for children lead to a wide range of test results 
reported in studies. The cut-off value used in the study by El-Kamary et al. was > 55 SFU/106 
cells (70). 
 
5.2.6( The(timing(of(vertical(transmission(and(early(cell(mediated(immune(
responses((paper(IV)(
We detected an HCV specific T cell (IFNγ) response towards viral antigens in vitro in some 
uninfected children already in the newborn period suggesting a pre- or perinatal exposure to 
viral antigens. As many as 60 % of the exposed/uninfected children had an IFNγ response 
before 3 months of age. In utero exposure to viral antigens might therefore be more common 
than previously thought.  It is unclear exactly when vertical transmission occurs, but based on 
when HCV-RNA is first detected in newborn children it is thought that approximately one 
third is infected during pregnancy and the rest during delivery (34, 150, 151).  
 
5.2.7( Is(HCV(specific(T(cell(reactivity(protective(of(infection?((paper(IV)(
One could speculate if exposure to viral antigens during pregnancy and subsequent 
development of HCV specific T cell reactivity contributes to some sort of protective 
immunity against vertical HCV infection. If this were true, we would have expected 
uninfected children to have a higher proportion of T cell responders than the vertically 
infected children. However, the proportion of T cell responders was almost equal in the two 
groups (67 % of the infected and 56 % of the uninfected) (Fig. 9A), suggesting that an HCV 
specific T cell response alone is not enough to protect from vertical infection. However, the 
vertically infected children were older and their T cell responses could have developed as a 
consequence of their chronic HCV infection, as shown in the chronically infected mothers.  
In chimpanzees, it has been demonstrated that HCV specific memory T cell responses are 
protective and associated with rapid virological control and clearance of HCV infection 
within 14 days when reinfected 7 years later (152). Similar results were found in another 
chimpanzee study where rechallenge took place 16 years after primary infection (68). In 
humans, reinfection challenge studies are not possible but by prospectively following 
individuals at high risk of reinfection, HCV specific immune responses and infection 
outcome can be investigated. Protective, but not sterilizing, immunity has been reported in 
IDUs, where reinfection yielded a shorter viremia period with lower HCV-RNA levels 
associated with broad IFNγ recall T cell responses (63). The rate of protective immunity 
might be underestimated, since a rapid clearance of reinfection might be missed if blood-
sampling frequency is too low. Others have confirmed these findings in similar settings, 
concluding that protective immunity depends on the breadth, quality and magnitude of HCV 
specific memory T cell responses (66).   
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6( CONCLUSIONS(AND(FUTURE(PERSPECTIVES(
Vertical transmission of hepatitis C virus is the most common transmission route in children. 
Even though our understanding of involved host and viral factors has increased, there is today 
no intervention to prevent HCV-VT. The only way to eliminate this risk is to eradicate the 
infection in fertile women, which is possible with the new treatment options. The main 
obstacle is to find the still undiagnosed, which puts new light on the importance of HCV 
screening of risk groups. The aim of this thesis was to investigate the transmission routes of 
HCV infection in children and below are the main conclusions described. 
•, In study I we found that blood transfusions in the neonatal period before 1992 
constitutes the transmission route in approximately 1.7 % of a cohort of chronic HCV 
patients in Stockholm. The finding of low awareness of previous blood transfusions 
and few clinical symptoms of chronic HCV in combination with the finding of liver 
cirrhosis in one of the four patients, suggests that efforts should be made to actively 
trace and screen this risk group for HCV.  
Patients treated at neonatal wards were pointed out as a special pediatric risk group in 
the national screening campaign in 2007-2010 but data analysis from the tested 
population shows that the campaign failed to reach this group. One explanation for 
this is probably the low awareness of previous hospital admittance in the neonatal 
period. Active tracing and testing of this risk group is thus needed. The best way 
would be to target only those with documented neonatal blood transfusions before 
1992, however, one obstacle might be the lack of digitalized transfusion records from 
that time. 
•, In study II we found a 10 times higher prevalence of chronic HCV infection among 
childhood cancer survivors in Stockholm compared to the general Swedish 
population. Active tracing screening was a better screening method than the general 
public screening campaign. The majority underwent successful antiviral treatment. In 
the era of highly effective DAA treatment, we recommend active tracing screening of 
all childhood cancer survivors.  
•, In study III we found no association of IL28B genotype and risk of vertical 
transmission. We conclude that, the in other settings favorable genotype C/C, is not 
protective of vertical transmission. The reason for the low vertical transmission rate of 
HCV remains unknown. Future studies on other possible host or viral factors involved 
in vertical HCV transmission are needed, for example exploring the role of NK cells 
and viral diversity. 
•, In study IV we found a high proportion of HCV specific T cell responders among 
exposed/uninfected children already from the newborn period, suggesting a prenatal 
exposure to viral antigens. The immune response persists up to least two years of age. 
HCV specific T cell response is a sign of previous viral encounter in the absence of 
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HCV antibodies. The frequency or magnitude of the CMI response was not higher 
than in vertically infected children, suggesting that CMI responses alone are not 
protective of vertical transmission. However, the T cell response in the vertically 
infected children might have developed as a consequence of their chronic HCV 
infection since they were older than the exposed/uninfected group.  
Future larger prospective studies on newborn children exposed to maternal HCV 
during pregnancy could better determine if a strong HCV specific T cell response 
early in life is associated with a lower risk of vertically transmitted chronic HCV 
infection. The results of the studies on HCV specific immune responses might be 
useful if the need for an HCV vaccine turns out to be necessary in the future, given 
for example possible DAA resistance development. 
(
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7( POPULÄRVETENSKAPLIG(SAMMANFATTNING(
Hepatit C är ett virus som infekterar levern. Det är en blodburen smitta som oftast blir kronisk 
och kan leda till utveckling av leverfibros, skrumplever och cancer. Hepatit C virus (HCV) 
infektionen är nästan alltid symtomfri, varför många bär på infektionen utan att veta om det. 
WHO har uppskattat att ca 6 miljoner barn världen över är HCV infekterade. Den vanligaste 
smittvägen för barn idag är smitta från modern under graviditet och förlossning. Tidigare var 
även blodtransfusion med smittat blod en vanlig smittkälla. År 1992 infördes allmän 
blodgivarscreening i Sverige för hepatit C, vilket medfört att den risken idag är obefintlig. 
Sedan några år tillbaka finns en mycket effektiv och nästan biverkningsfri tablettbaserad 
behandling mot hepatit C som ger nästintill 100 % utläkning. Denna behandling är idag 
godkänd för barn över 12 år. För att kunna minska fortsatt spridning av viruset och därmed 
minska risken för leversjukdom är det viktigt att vi hittar alla de som fortfarande är 
odiagnostiserade. Syftet med denna avhandling har varit att studera smittvägar samt 
epidemiologiska och immunologiska aspekter av hepatit C exponering tidigt i livet. 
I studie I undersöktes om blodtransfusioner givna under nyföddhetsperioden kunde förklara 
smittvägen hos de med kronisk HCV infektion där smittvägen var okänd. Vi inkluderade 230 
patienter födda 1960-75 med kronisk HCV infektion och studerade deras journaler. Av dessa, 
hade 98 okänd smittväg och 128 känd smittväg. Fyra av 230 (1.7 %) hade fått blodtransfusion 
som nyfödda och detta var den mest sannolika smittvägen i samtliga fall. Ingen av dem var, 
vid tiden för hepatit C diagnosen, medvetna om att de fått blod i nyföddhetsperioden. Tre av 
dem genomgick behandling och läkte ut sin hepatit C. 
I studie II undersöktes 676 nu vuxna patienter som under barndomen behandlats för cancer i 
Stockholm före 1992 (när blodgivarscreening infördes). Blodtransfusioner är vanliga vid 
cancerbehandling och dessa patienter räknas därför som särskild riskgrupp för 
transfusionsöverförd HCV smitta. Vi undersökte med hjälp av journaler och register hur 
många som var HCV testade och hur många som var HCV infekterade. Vi fann att 233 av 
676 (34 %) var HCV testade, och 11 av dem (5 %) var infekterade. Andelen infekterade i 
denna grupp patienter visade sig vara 10 gånger högre än i den svenska befolkningen. De 
patienter som år 2017 bodde i Stockholms län och sannolikt var otestade inkluderades i en 
screening där vi aktivt sökte upp och erbjöd dessa patienter HCV test. Denna 
screeningstrategi visade sig vara betydligt mer effektiv avseende antalet testade jämfört med 
en tidigare nationell HCV screeningkampanj där alla som fått blod före 1992 via media 
uppmanades gå och testa sig.  
I studie III undersöktes om en genetisk variant av en immunsignalmolekyl, kallad IL28B, 
påverkar risken att en mor smittar sitt barn under graviditet eller förlossning (s.k. vertikal 
smitta). Denna risk beräknas generellt vara ca 5 % och är oberoende av förlossningssätt och 
amning. Däremot ger hög virusnivå hos modern ökad risk att barnet blir smittat. IL28B 
genotyp har i tidigare studier visat sig ha betydelse för spontan utläkning av kronisk HCV 
infektion samt för utläkningsfrekvensen vid interferonbaserad behandling (den äldre typen av 
behandling). Vi inkluderade 59 mödrar med kronisk HCV infektion och 123 barn till 
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infekterade mödrar, varav 47 infekterade och 76 oinfekterade. Varken barnens eller 
mödrarnas IL28B genotyp visade sig ha någon betydelse för smittöverföringsrisken. 
I studie IV studerades HCV specifikt immunsvar (T cellssvar) hos barn till HCV infekterade 
mödrar. Förekomsten av virusspecifikt T cellssvar är ett tecken på immunologiskt minne, dvs 
att T cellerna tidigare har stött på samma viruspartikel. T cellssvaret hos barn och mammor 
undersöktes med två olika labmetoder som dels mäter hur mycket gammainterferon 
(signalmolekyl med antiviral verkan) T cellerna producerar, dels hur snabbt de delar sig när 
de utsätts för HCV proteiner. Vi kunde påvisa ett HCV specifikt T cellssvar hos 73 % av 
mödrarna, hos 67 % av infekterade barn och hos 56 % av de exponerade men oinfekterade 
barnen. T cellsvaret fanns redan hos nyfödda barn vilket indikerar att de har exponerats för 
viruspartiklar redan under graviditeten (eftersom det tar viss tid för ett T cellssvar att 
utvecklas). Vi kunde inte påvisa någon signifikant skillnad mellan infekterade och 
exponerade/oinfekterade barn, däremot hade båda exponerade barngrupperna högre andel 
med T cellssvar än friska nyfödda barn till osmittade mammor. I gruppen smittade barn 
ingick barn i åldrarna 0-18 år och i exponerade/oinfekterade gruppen 0-2 år. Det faktum att så 
många osmittade men HCV exponerade barn hade ett HCV specifikt T cellssvar tyder på att 
virusexponering under graviditet och förlossning kan vara vanligare än man tidigare trott. Det 
är möjligt att detta svar bidrar med någon form av medfött immunologiskt skydd mot 
vertikalsmitta. För att kunna fastställa om T cellssvaret har någon skyddande effekt behövs 
fler liknande studier med tillräckligt många nyföddhetsprover av både oinfekterade och 
infekterade HCV exponerade barn. 
Sammanfattningsvis, mot bakgrund av våra resultat där vi fann låg medvetenhet och låg andel 
HCV testade i kombination med hög andel smittade, rekommenderas aktiv spårning och 
testning av personer tillhörande riskgrupper för HCV transfusionssmitta. Vi fann inget 
samband mellan IL28B genotyp och mor-barn smitta, men däremot en hög andel exponerade 
men oinfekterade barn som hade HCV specifikt T cellssvar redan i nyföddhetsperioden vilket 
indikerar att exponering för viruspartiklar under graviditeten sannolikt är vanligare än man 
tidigare trott. 
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